Back to mobile site

BioXcel Therapeutics (BTAI) PT Lowered to $21 at Goldman Sachs

December 1, 2021 11:05 AM EST Send to a Friend
Goldman Sachs analyst Corinne Jenkins lowered the price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login